KBY Biotech Indexv0.0.34
Search
← Pipeline|Liralucimab

Liralucimab

Phase 2
ARC-4893
By Arcturus
Source: Trial-derived·Trials: 1
Modality
Radioligand
MOA
SOS1i
Target
AHR
Pathway
T-cell
GISTPompe
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
Aug 2019
Phase 2Current
NCT06059710
2,519 pts·Pompe
2019-08→TBD·Recruiting
2,519 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2
Recruit…
Recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT06059710Phase 2PompeRecruiting2519EASI-75
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-2901PfizerPhase 2AHRSOS1i
MRK-1380Merck & CoPreclinicalSHP2SOS1i
TerarelsinAbbViePreclinicalSOS1SOS1i
AZN-1715AstraZenecaPhase 3AHRFXIai
DoxarapivirBristol-Myers SquibbPhase 3KRASG12CSOS1i
BAY-6520BayerPhase 2AHRTROP-2 ADC
DSN-6862Daiichi SankyoPreclinicalIL-23SOS1i
GIL-2011Gilead SciencesPreclinicalVEGFSOS1i
REG-647RegeneronPreclinicalSMN2SOS1i
CevisacituzumabAlnylamPreclinicalMALT1SOS1i